This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: ABSTRACT 1 Effective diabetic kidney disease (DKD) biomarkers remain elusive, and urinary 2 microRNAs (miRNAs) represent a potential source of novel non-invasive disease 3 sentinels. We profiled 754 miRNAs in pooled urine samples from DKD patients (n = 20), 4 detecting significantly increased miR-126, miR-155 and miR-29b compared to controls 5 (n = 20). These results were confirmed in an independent cohort of 89 DKD patients, 6 62 diabetic patients without DKD and 41 controls: miR-126 (2.8-fold increase; R e la t iv e e x p r e s s io n m iR -2 9 b G P T D T 0 1 2 3 4 Rela>ve expression miR-29b G PT DT H P T C F ib r o b la s t P o d o c yt e G E n C 0 1 2 3 4 R e la t iv e e x p r e s s io n m iR -2 9 b * Rela>ve expression miR-29b PTC Fibroblast Podocyte GEnC
7 p<0.0001), miR-155 (1.8-fold; p<0.001) and miR-29b (4.6-fold; p = 0.024). Combined 8 receiver operating characteristic curve analysis resulted in an area under the curve of 9 0.8. A relative quantification threshold equivalent to 80% sensitivity for each miRNA 10 gave a positive signal for 48% of DKD patients compared to 3.6% of diabetic patients 11 without DKD. Laser capture microdissection of renal biopsies followed by RT-qPCR 12 detected miR-155 in glomeruli, proximal and distal tubules, while miR-126 and miR-13 29b were most abundant in glomerular extracts. Subsequent experiments showed 14 miR-126 and miR-29b enrichment in glomerular endothelial cells (GEnCs) compared to 15 podocytes, proximal tubular epithelial cells and fibroblasts. Significantly increased miR-16 126 and miR-29b were detected in GEnC conditioned medium in response to tumour 17 necrosis factor-alpha and transforming growth factor-beta 1, respectively. Our data 18 reveal an altered urinary miRNA profile associated with DKD and link these variations 19 to miRNA release from GEnCs. 20 Recent estimates suggest that 1 in 12 of the global population suffers from diabetes 41 mellitus, approximately 40 % of those affected will go on to develop diabetic kidney 42 disease (DKD). 1 DKD is the leading cause of end-stage renal disease and predisposing 43 factors include genetic causes, ethnicity, hyperglycaemia, insulin resistance, 44 intraglomerular hypertension and hyperfiltration. 2,3 45 Hyperglycaemia results in numerous deleterious consequences including 46 upregulated cytokine synthesis, renin-angiotensin system activation, generation of 47 advanced glycation end products and reactive oxygen species, and increased protein 48 kinase C activity. 4, 5 Nitric oxide and NF-κB pathway-driven loss of endothelial and 49 vascular modulation have been implicated in insulin resistance, and early DKD may 50 be associated with insulin signaling defects specific to the podocyte. 6 These insults 51 result in loss of glomerular filtration rate and ultimately to renal failure from 52 mesangial hyperexpansion, nodular glomerulosclerosis and tubulointerstitial 53 fibrosis. 7 54
Detection of urinary microalbuminuria currently forms the basis of DKD 55 progression monitoring, varying from normal mean albuminuria values around 10 56 mg/day to a diagnosis of microalbuminuria at 30-300 mg/day and macroalbuminuria 57 above 300 mg/day. 8 Prognosis is complicated, since not all microalbuminuric 58 patients progress to overt nephropathy. A number of novel biomarkers have been 59 assessed for utility in DKD but none are being used as routine clinical markers, and 60 they may lack specificity and sensitivity to predict individual DKD patient outcomes. 61
In light of the above, novel markers that can discriminate aetiology, progression 62 and/or response to treatment remain highly desirable. 63
MicroRNAs (miRNAs) are ubiquitously-expressed short noncoding RNAs that 64 regulate the expression of most protein coding genes in the human genome, and 65 detection of miR-192, miR-194, miR-215, miR-216, miR-146a, miR-204 and miR-886 66 is elevated in the kidney. 9 Urinary miRNAs represent a highly promising novel source 67 of non-invasive biomarkers that are stabilised via argonaute 2 protein/exosome 68 association and are rapidly and precisely detected by RT-qPCR. 10 69
Reports have suggested a role for miRNAs in the pathology of DKD, 11,12 70 including previous work from this laboratory showing decreased miR-192 in biopsies 71 from late-stage DKD patients with diminished renal function. 13 However, 72 comparatively little is known about the abundance of urinary miRNAs in DKD 73
patients. 74
We hypothesised that alterations in urinary miRNA profiles would be 75 associated with DKD. We identified candidate DKD biomarkers by comparing miRNA 76 profiles in urine samples from a patient discovery cohort with those from unaffected 77 controls. Selected candidates were then measured in a larger, independent cohort. 78
Subsequently, laser capture microdissection of renal biopsies and in vitro cell culture 79 were used to investigate the sources of our candidate urinary miRNA DKD 80 biomarkers with respect to nephron domain and cell type. Accordingly, CKD should be attributable to diabetes in the presence of 88 macroalbuminuria (in the absence of urinary infection), or in the presence of 89 microalbuminuria with concomitant diabetic retinopathy, or in type 1 diabetes of at 90 least 10 years duration. 14 The initial profiling study cohort of 20 DKD patients and 20 91 healthy controls was obtained from the Wales Kidney Research Tissue Bank, 92
University Hospital of Wales, Cardiff. The DKD group was predominantly male (85%), 93 mean age 72 years (SD +/-8.7). DKD patients were CKD stage 3-5 (pre-dialysis), with 94 mean eGFR of 29 ml/min/1.73m 2 (SD +/-8.5) and a mean urinary Albumin:Creatinine 95 ratio (ACR) of 13.5 mg/mmol (SD +/-14.5). The control group (n = 20) in the profiling 96 cohort were 50% male, mean age 47 years (SD +/-11.0) with no microalbuminuria 97 (ACR<3 mg/mmol). For further details on ACR categories see Table 1 . 98
99
The confirmation cohort was drawn from two secondary care facilities: the Wales 100 
Urine Collection, RNA Isolation and RT-qPCR analysis 127
Urine samples were collected and RNA extraction from 350 µl of urine, generation of 128 cDNA from equal volumes of RNA extracts and RT-qPCR were then carried out as 129 described in detail elsewhere. 10 TaqMan assays (Thermo Fisher Scientific, Paisley, 130 UK) used in this study were: hsa-miR-29b-3p (ID 000413); hsa-miR-126-3p (ID 131 002228); hsa-miR-155-5p (ID 002623); hsa-miR-191-5p (ID 002299). Relative 132 quantities were calculated using the 2 -ΔΔCt method, and miRNA expression was 133 normalized to hsa-miR-191-5p. 10 To exclude the possibility that gender, age and eGFR status had extreme effects on 146 miRNA expression profiles, the following pooling strategy was followed. Control pool 147 Human conditionally immortalised glomerular endothelial cell (GEnC) and human 167 podocyte (ATC) cell lines were propagated at 33°C as described previously. 19, 20 After 168 5 (GEnC) and 14 (ATC) days, cells were transferred to 37°C incubation to inactivate 169 the SV40 T antigen and permit differentiation, prior to experimental use. Where 170 stated, GEnCs were growth arrested for 24 h and then treated with TNF-α (10 171 ng/mL) or TGF-β1 (1 ng/mL) at either normoglycaemic (5 mM) or hyperglycaemic (25 172 mM) D-glucose concentrations for 24 h. Proximal tubular epithelial cell (PTC) line HK-173 2 21 and fibroblast 22 cultures were maintained as described elsewhere. Cells and 174 culture medium obtained from each well were used for RNA extraction as described 175
above. 176

Statistical analysis 178
MiRNA profiling data were analysed using Thermo Fisher Scientific's DataAssist 179 Software (version 3.01), NormFinder Software (http://moma.dk/normfinder-180 software; last access 21/02/18) and GraphPad Prism 6 (version 6.0d). Pearson 181
Correlation Coefficients was used to detect clusters of similarity in miRNA threshold 182 cycle values between each pool group in patients, and between each pool group in 183 controls. To identify a suitable reference gene for the normalization of miRNA 184 expression in this study, the NormFinder algorithm was applied to the expression 185 data obtained from the Human TaqMan miRNA Arrays. Analysis comparing miRNA 186 levels between subjects with DKD and controls was carried out using GraphPad Prism 187 version 6 version 6.0d. Values for p below 0.05 were considered statistically 188 significant. MiRNA profiling data sets can be found in Gene Expression Omnibus 189 (https://www.ncbi.nlm.nih.gov/geo; accession number GSE114477). 190
191
Results 192
Altered urinary miRNA detection in DKD patients 193
To select candidate miRNAs that may act as DKD biomarkers, we first compared data 194 from unbiased expression profiling of 754 miRNAs in urine samples from 20 DKD 195 patients and 20 unaffected controls. Analyses were performed on 4 patient and 4 196 control pools, each composed of urine samples from 5 individuals as recommended 197
by Zhang and colleagues. 23 Samples were pooled prior to profiling to minimize the 198 contribution of subject to subject variation and to make substantive features easier 199 to find, and thereby identify biomarkers common across individuals. 24 Previous 200 analysis suggested that 40 individuals might optimally be pooled across 8 arrays, 23 201 which was our chosen pooling approach. 202
In Figure 1A change were subsequently selected as potential candidate biomarkers for further 208
analysis. 209
Specific RT-qPCR assays were then used to analyse these miRNAs in each 210 component urine sample pooled for profiling analysis. Statistically significant 211 differences in miRNA detection between DKD patient and control urine samples 212
were replicated for miR-126 (4.3-fold increase; p = 0.0087), miR-155 (22.9-fold; p = 213 0.0024) and miR-29b (4.9-fold; p = 0.0002) (Figure 1, C Significant differences were again seen between DKD patients and controls 227 for miR-126 (2.8-fold increase; p<0.0001; Figure 2A ), miR-155 (1.8-fold; p<0.001; 228 Figure 2B ) and miR-29b (4.6-fold; p = 0.024; Figure 2C ). Comparison of DKD patients 229 with diabetic patients without DKD was statistically significant for miR-126 (3.1-fold 230 increase; p<0.0001) and miR-155 (1.6-fold; p = 0.024) with a trend to increased miR-231 29b (4.1-fold; p = 0.121) (Figure 2A-C) . 232
RT-qPCR data for all 3 miRNAs were used to compare DKD patients and 233 diabetic patients without DKD in the combined receiver operating characteristic 234 (ROC) curve analysis shown in Figure 2D , giving an area under the curve (AUC) of 235 0.80. To analyse the contributions of each miRNA to the above ROC curve, individual 236 specificity and likelihood ratios were calculated for relative expression (RQ) values 237 equivalent to a sensitivity of 80%. 25, 26 Data displayed in Table 2 illustrate the 238 magnitude of corresponding specificity values was miR-126 > miR-155 > miR-29b, 239
and that combined miRNA data resulted in a ≥6.5% increase in specificity and 240 likelihood ratio compared with individual miRNAs. These RQ data were then used as 241
consecutive threshold values to discriminate between DKD and diabetic patients 242 without DKD (D in Table 3 ) from the independent cohort. The discriminatory order 243 was miR-29b (DKD/D = 5.62) > miR-126 (3.48) > miR-155 (2.23), and RQ values 244 exceeding all 3 thresholds were obtained for 48.0% of DKD patients compared with 245 3.6% of diabetic patients without DKD (Table 3) . In the present study we used laser capture microdissection (LCM) to isolate 254 glomeruli, proximal and distal tubules ( Figure 3A ) from histologically normal 255 formalin-fixed, paraffin-embedded (FFPE) renal biopsy samples, and analysed miR-256 126, miR-155 and miR-29b expression by RT-qPCR. In Figure 3B , a typical CD10-257 stained FFPE biopsy section is seen before and after LCM to isolate glomeruli, 258 proximal and distal renal tubules. MiR-126, miR-155 and miR-29b were detected in 259 extracts from all three nephron regions (Figure 3 , C-E). Increased glomerular 260 abundances were observed for miR-126 ( Figure 3C ) and miR-29b ( Figure 3E ), while 261 miR-155 was most abundant in the distal tubule ( Figure 3D) . 262
Conclusions regarding nephron region-specific miRNA expression from the 263 above analyses are inherently limited, however, since tissue extracts are subject to 264 trace contamination by cells from other nephron domains. Therefore, cellular miRNA 265 localisation within each nephron region was subsequently investigated by RT-qPCR 266 analysis of podocyte and endothelial cell (GEnC) cultures from the glomerulus, renal 267 proximal tubular epithelial cells (PTC) and fibroblasts. Detection of miR-126 was 268 significantly higher in GEnCs compared with other cell types ( Figure 3F ). Most miR-269 155 was detected in PTCs and least in GEnCs ( Figure 3G ), while miR-29b was most 270 abundant in GEnCs ( Figure 3H) . The presence of TNF-α led to significantly increased miR-126 detection in 282
GEnC conditioned medium at 5 mM and 25 mM D-glucose ( Figure 4B ), a pattern also 283 seen for miR-29b following TGF-β1 addition ( Figure 4D ). These cytokines did not 284 increase GEnC expression of miR-126 ( Figure 4A ), or miR-29b ( Figure 4C ), a pattern 285 consistent with increased release, but not expression, of miRNAs. 286
No significant changes in miR-155 were detected in response to elevated D-287 glucose with either cytokine, and data for TNF-α are shown (Figure 4, E and F) . 288
Similarly, changes in miR-126 following TGF-β1 addition, and for miR-29b in the 289 presence of TNF-α, were not observed (data not shown). Elevated D-glucose alone 290 did not change miRNA expression in GEnCs or conditioned medium (Figure 4, A-F) . miRNA quantification might provide data on ongoing pathological processes, and so 308 aid patient stratification and measurement of response to therapy. 309
Urinary miRNA biomarkers have several potential significant advantages over 310 circulating miRNAs for adoption into existing treatment pathways alongside current 311 biomarkers, including speed and cost of non-invasive sample access. 29 However, few 312 urinary miRNA DKD biomarker data have so far been reported. Previous studies have 313 focused on circulating miRNAs, and have generated conflicting data with respect to 314 association of miR-126 with diabetes mellitus and/or DKD. A recent cross-sectional 315 analysis of type 2 diabetes mellitus patients found a negative association with 316 plasma miR-126, 30 and similar findings have been reported for type 1 diabetes 317 mellitus and all complications. 31 By contrast, miR-126 detection did not change in 318 whole blood from type 2 diabetes mellitus patients and control subjects, but 319 decreased in DKD patient samples. 32 Furthermore, no change in plasma miR-126 was 320 observed in a study of paediatric type 1 diabetic patients. 33 GEnCs and podocytes has been proposed. 35 In addition, miR-126 repression of 333 vascular cell adhesion molecule 1 expression in human umbilical vein endothelial 334 cells regulates their response to pro-inflammatory adhesion molecules. 36 MiR-126 335 has also been implicated in the heterogenic inflammatory response of renal 336 microvascular endothelial cells. 37 337
Increased expression of miR-155 has been observed in DKD patient renal 338 biopsies, in close correlation with increased serum creatinine. 38 Furthermore, miR-339 155 deficiency attenuated renal damage and IL-17 expression was downregulated in 340 streptozotocin-induced DKD mice. 39 Together with miR-126, miR-155 has been 341 implicated in multiple forms of vascular remodelling and associated with 342 cardiovascular disease. 40 343
Decreased miR-29b has been reported in early and advanced animal models 344 of diabetic renal fibrosis. 41 Chen and colleagues found that loss of renal miR-29b in 345 db/db mice led to increased albuminuria, TGF-β-mediated fibrosis and immune 346 injury, while restored miR-29b expression inhibited renal injury. 42 Indeed, while we 347 have focused on upregulated miRNAs in this study, we acknowledge the potential 348 importance of miRNA downregulations that we detected. 349
In the present study we localized miR-29b to the glomerular endothelium. 350
Reduction of collagen and laminin synthesis has been reported following forced miR-351 29b expression in human corneal endothelial cells. 43 In apoE knockout mice, miR-29b 352 induced aortic endothelial permeability in response to a high fat diet, and brought 353 about aortic apoptosis by direct targeting of melatonin receptor mt1. 44 In addition, 354 upregulated miR-29b expression has been observed in human umbilical vein 355 endothelial cells exposed to hyperglycaemia. 45 356
The cytokine-driven release from GEnCs observed for miR-126 (TNF-α) and 357 miR-29b (TGF-β1) reported here suggests that these cells may be the principal 358 source of elevated urinary miR-126 and miR-29b detected in DKD. We speculate that 359 this constitutes evidence for disease-related signalling down the nephron that will be 360 interesting to test in future studies. Indeed, we have demonstrated association of 361 urinary miRNAs with exosomes 10 and exosomal transport, which might facilitate 362 passage of miRNAs through the nephron, has been reported for all three candidate 363 biomarker miRNAs. 364
Exosome-mediated release of miR-126 from CD34 + peripheral blood 365 mononuclear cells is proangiogenic, and decreased miR-126 was detected in 366 elevated glucose cell culture and diabetic patients. 46 MiR-155 is depleted in urinary 367 exosomes from microalbuminuric type 1 diabetes mellitus patients. 47 Endogenous 368 miR-29b, spontaneously released from beta-cells within exosomes, stimulates TNF-369 α secretion from spleen cells isolated from diabetes-prone NOD mice in vitro. 48 370
In summary, we have used unbiased profiling approaches to identify a urinary 371 miRNA signature associated with DKD, and have subsequently confirmed increased 372 miR-126, miR-155 and miR-29b in an independent patient cohort. MiR-126 and miR-373 29b were identified as enriched in GEnCs, and released from these cells in response 374
to DKD-related cytokines. Urinary miR-126, miR-155 and miR-29b are therefore 375 promising DKD biomarkers, and the potential pathological significance of miR-126 376 and miR-29b release from GEnCs merits further evaluation. 377
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